Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alliance Pharma posts strong results after audit delay

(Sharecast News) - Alliance Pharma reported strong preliminary results for the year ended 31 December on Wednesday, after an audit delay, driven by a robust second half that led to record sales and expanded underlying profit. The AIM-traded firm said consumer healthcare revenue increased 11% at constant exchange rates (CER) to £136.4m, up 9% on a reported basis, with the Kelo-Cote franchise showing significant recovery in the second half, achieving a 29% revenue increase to £63.2m.

Prescription medicine revenue remained stable at £46.3m.

Non-cash impairments totaled £79.3m, due to lower future cash flow expectations and a higher cost of capital, impacting assets like Amberen, Nizoral, and other smaller assets.

A correction of prior year valuation errors added £28.3m to the 2022 non-cash impairment charges.

Underlying profit before tax rose by 4% to £31.5m, while the reported loss before tax widened to £48.8m, from a restated loss of £23.1m in 2022.

Free cash flow grew 35% to £21.3m, and net debt narrowed to £91.2m, bringing group leverage to 2.05x.

The board said it had paused dividends to prioritise reinvestment for business growth.

Its latest US acquisition, ScarAway, performed strongly with £9.9m in revenue, exceeding expectations.

Internal development projects generated £3.5m in revenue, and e-commerce expansions were planned for 2024.

Operational efficiencies included moving Nizoral manufacturing to Thailand, resulting in cost savings and improved delivery performance.

Environmental initiatives achieved a 48% reduction in scope one and two emissions, with targets set for net zero by 2030 and scope three emissions by 2044.

Alliance Pharma noted that it was re-certified as a 'Great Place To Work' in the UK, US, China, and Singapore.

The board was meanwhile strengthened with several new appointments, including a new chair, Camillo Pane, and a new chief executive officer, Nick Sedgwick.

Additionally, the company successfully appealed a Competition and Markets Authority decision, releasing a £7.9m provision for a potential fine.

"Whilst the audit delay has been unsatisfactory, it has allowed us to implement a more robust intangible valuation review process," said chief financial officer Andrew Franklin.

"Despite the non-cash impairments our portfolio continues to provide a solid platform from which to grow our consumer healthcare brands and generate strong cash flow.

"In 2023, we increased marketing investment, launching award winning advertising campaigns for Kelo-Cote and MacuShield to accelerate organic sales growth whilst bringing new products to market."

Franklin said the company's revenues through e-commerce were building strongly, as it strengthened its network of specialist partners and internal capabilities and entered new geographies.

"We remain confident in our medium to long-term performance as we focus our resources on those market segments in which we already have a strong presence and expertise in order to drive solid organic revenue growth above that of the broader consumer healthcare market."

At 0915 BST, shares in Alliance Pharma were up 7.04% at 38p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

CyanConnode metering project in Goa now fully funded
(Sharecast News) - CyanConnode announced on Monday that its milestone smart metering project in Goa, awarded in April, was now fully funded and would proceed without the need for additional capital from the company.
Manolete secures £3.2m truck cartel claim settlement
(Sharecast News) - Manolete Partners announced on Monday that it has secured a £3.2m settlement in one of its truck cartel claims, representing a strong cash return on investment despite a related non-cash write down to its balance sheet.
Portmeirion reports modest sales growth, 'immediate' tariff impact
(Sharecast News) - Portmeirion Group reported a modest increase in sales for the first half on Monday, as strong growth in South Korea and international markets helped offset a sharp decline in the United States caused by new import tariffs.
Sunrise signs option agreement over 'non-core' Hazen Project
(Sharecast News) - Sunrise Resources announced the signing of an option agreement on Monday, granting a US-based company the exclusive right to acquire its Hazen Project in Nevada for $0.8m in cash.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.